Lost in translation. The quest for definitions of treatment-resistant depression with a focus on inflammation-related gene expression

Luca Sforzini

doi:10.1016/j.bbih.2021.100331

Lost in translation. The quest for definitions of treatment-resistant depression with a focus on inflammation-related gene expression

Luca Sforzini

Psychological Medicine

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Approximately one third of individuals with major depressive disorder (MDD) do not respond to antidepressant treatments; but what does treatment-resistant depression (TRD) mean? With this article, I aim to provide an overview of the clinical and operational criteria currently used to define TRD, highlighting core gaps in knowledge and open questions to be addressed in order to drive future research in the field. Importantly, a better definition of TRD must include a better characterization of the biological and molecular correlates of non-response. Among these potential biomarkers, compelling evidence reveals a potential role of inflammation-related gene expression signatures. A more accurate clinical and etiopathological characterization of TRD subjects may help to identify biologically based MDD clinical phenotypes to be targeted in future research and finally achieve better outcomes.

Original language	English
Article number	100331
Journal	Brain, Behavior, and Immunity - Health
Volume	16
DOIs	https://doi.org/10.1016/j.bbih.2021.100331
Publication status	Published - Oct 2021

Keywords

Biomarkers
Genome-wide gene expression
Major depressive disorder (MDD)
RNA-seq
Transcriptomics
Treatment-resistant depression (TRD)

Access to Document

10.1016/j.bbih.2021.100331

Cite this

@article{79e67814f0c94e2c86ed8b3cc57a5907,

title = "Lost in translation. The quest for definitions of treatment-resistant depression with a focus on inflammation-related gene expression",

abstract = "Approximately one third of individuals with major depressive disorder (MDD) do not respond to antidepressant treatments; but what does treatment-resistant depression (TRD) mean? With this article, I aim to provide an overview of the clinical and operational criteria currently used to define TRD, highlighting core gaps in knowledge and open questions to be addressed in order to drive future research in the field. Importantly, a better definition of TRD must include a better characterization of the biological and molecular correlates of non-response. Among these potential biomarkers, compelling evidence reveals a potential role of inflammation-related gene expression signatures. A more accurate clinical and etiopathological characterization of TRD subjects may help to identify biologically based MDD clinical phenotypes to be targeted in future research and finally achieve better outcomes.",

keywords = "Biomarkers, Genome-wide gene expression, Major depressive disorder (MDD), RNA-seq, Transcriptomics, Treatment-resistant depression (TRD)",

author = "Luca Sforzini",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = oct,

doi = "10.1016/j.bbih.2021.100331",

language = "English",

volume = "16",

journal = "Brain, Behavior, and Immunity - Health",

issn = "2666-3546",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Lost in translation. The quest for definitions of treatment-resistant depression with a focus on inflammation-related gene expression

AU - Sforzini, Luca

PY - 2021/10

Y1 - 2021/10

N2 - Approximately one third of individuals with major depressive disorder (MDD) do not respond to antidepressant treatments; but what does treatment-resistant depression (TRD) mean? With this article, I aim to provide an overview of the clinical and operational criteria currently used to define TRD, highlighting core gaps in knowledge and open questions to be addressed in order to drive future research in the field. Importantly, a better definition of TRD must include a better characterization of the biological and molecular correlates of non-response. Among these potential biomarkers, compelling evidence reveals a potential role of inflammation-related gene expression signatures. A more accurate clinical and etiopathological characterization of TRD subjects may help to identify biologically based MDD clinical phenotypes to be targeted in future research and finally achieve better outcomes.

AB - Approximately one third of individuals with major depressive disorder (MDD) do not respond to antidepressant treatments; but what does treatment-resistant depression (TRD) mean? With this article, I aim to provide an overview of the clinical and operational criteria currently used to define TRD, highlighting core gaps in knowledge and open questions to be addressed in order to drive future research in the field. Importantly, a better definition of TRD must include a better characterization of the biological and molecular correlates of non-response. Among these potential biomarkers, compelling evidence reveals a potential role of inflammation-related gene expression signatures. A more accurate clinical and etiopathological characterization of TRD subjects may help to identify biologically based MDD clinical phenotypes to be targeted in future research and finally achieve better outcomes.

KW - Biomarkers

KW - Genome-wide gene expression

KW - Major depressive disorder (MDD)

KW - RNA-seq

KW - Transcriptomics

KW - Treatment-resistant depression (TRD)

UR - http://www.scopus.com/inward/record.url?scp=85122657415&partnerID=8YFLogxK

U2 - 10.1016/j.bbih.2021.100331

DO - 10.1016/j.bbih.2021.100331

M3 - Article

AN - SCOPUS:85122657415

SN - 2666-3546

VL - 16

JO - Brain, Behavior, and Immunity - Health

JF - Brain, Behavior, and Immunity - Health

M1 - 100331

ER -

Lost in translation. The quest for definitions of treatment-resistant depression with a focus on inflammation-related gene expression

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this